EditorialAsthma: still more questions than answers
References (0)
Cited by (19)
Animal models of asthma: Value, limitations and opportunities for alternative approaches
2011, Drug Discovery TodayCitation Excerpt :The extent of the problem was summed up in a 2008 Lancet editorial: ‘Progress in understanding asthma and its underlying mechanisms is slow; treatment can be difficult and response unpredictable; and prevention or cure is still a pipedream. Asthma, one of the most important chronic diseases, remains a genuine mystery’ [17]. Most patients with asthma have mild to moderate forms of the disease, and are well controlled with the mainstay of available therapy: anti-inflammatory drugs especially inhaled glucocorticosteroids, leukotriene modifiers and bronchodilators, such as the short and long-acting β2-adrenoceptor-selective agonists (β2-agonists).
Rethinking the Pathogenesis of Asthma
2009, ImmunityCitation Excerpt :However, the question that needs to be asked is whether this dependence on suppressive drugs is an end in itself or whether we should be aspiring to higher gains for asthma sufferers. As the editor of the Lancet highlighted in a recent issue of this journal dedicated to asthma, “Progress in understanding asthma and its underlying mechanisms is slow; treatment can be difficult and response unpredictable; and prevention and cure are still a pipedream” (The Lancet, 2008). So where do we go from here?
Fluticasone propionate in clinically suspected asthma patients with negative methacholine challenge test
2017, Clinical Respiratory JournalAsthma on the move: how mobile apps remediate risk for disease management
2016, Health, Risk and SocietyEffects of whole-body exercise and inspiratory muscle training in people with asthma
2015, Therapeutic Physical Activities for People with Disability